Why Education Is Key When It Comes To Medicine

Shamir Patel | Posted 28.08.2017 | UK
Shamir Patel

It's been a long-fought battle in the pharmaceutical industry. And now, consumer watchdog Which? has uncovered how some drugs firms are selling pain pills for 10 times the price of generic alternatives. It has never been a secret: it's just a matter of education.

Why I'm Fighting The Ultimate 'Sexist Surcharge'

Shamir Patel | Posted 22.08.2017 | UK Lifestyle
Shamir Patel

Imagine the scenario: It's late at night and your partner wakes feeling desperately poorly with a headache. You run downstairs, check the cupboard, and realise that you're out of painkillers. Determined to help ease their suffering, you drive to the nearest shop, reach for the ibuprofen and take it to the till.

Fix The Problems: Written Medicine's Research Paradox Two

Murtada Alsaif | Posted 14.11.2016 | UK Tech
Murtada Alsaif

Our solution to this problem was to increase the number of languages and the number of pharmacies enrolled so that each pharmacy can give us fewer surveys and we can still hit data collection targets.

Nurofen Back Pain Advert Banned For 'Misleading' Customers

The Huffington Post | Natasha Hinde | Posted 29.06.2016 | UK Lifestyle

A Nurofen TV advert has been banned by the UK's advertising watchdog for misleading customers by telling them their pills specifically target back pai...

Drug Regulatory Authority: A Case for Hope?

Dr Sania Nishtar | Posted 09.02.2013 | UK
Dr Sania Nishtar

The new drug regulatory authority does present a case for hope, but if the systemic impediments and potential distortions and loopholes in the law are not addressed, it may lead to an even worse failure than what the earlier red-tape variant of drug regulation resulted in.

The Future for Market Research

Sarah Phillips | Posted 01.12.2012 | UK
Sarah Phillips

The commercial backdrop for any pharmaceutical company bringing a product to market is the changing market landscape they face. This is largely one of fragmentation, both in terms of the types of patient who are appropriate for targeting and in terms of the disease.

A Profession by Any Other Name - The Shame of Market Research

Sarah Phillips | Posted 01.10.2012 | UK
Sarah Phillips

I was carving a loaf of bread this weekend, with my new bread knife. For some reason, I didn't look at the knife and think to myself, 'Wow, that's some knife skills you have, maybe you could be a surgeon'.

Drugmaker AstraZeneca To Slash 7,300 Jobs As Profits Slip

PA | Posted 02.02.2012 | UK

Pharmaceuticals giant AstraZeneca said today that it will axe 7,300 jobs by the end of 2014 as part of a fresh round of cost savings. The company, ...

Behind the Conflicting Headlines: What do the Results of Trials of Avastin for Ovarian Cancer Actually Show?

Annabelle South | Posted 19.03.2012 | UK
Annabelle South

We urgently need to improve how women with ovarian cancer are treated. I hope that further results from the ICON7 trial that are due out over the next year or so will bring us the knowledge to do this.

Taking Slightly Too Much Paracetamol 'Can Cause Death'

PA | Posted 23.11.2011 | UK Lifestyle

People who regularly take slightly too much paracetamol over a period of time to relieve pain could be at a higher risk of dying than those who take a...

Hermann Hauser - the Best Years for Technology Growth are to Come

Ellee Seymour | Posted 17.12.2011 | UK Tech
Ellee Seymour

Dr Hermann Hauser and David Cleevely continue to have a huge influence on business in the UK today and are founders, directors and investors of many Cambridge companies. They shared their vision for our future prosperity and growth with Cambridge Network members in a discussion entitled, Projections for the future of Cambridge.

What's In A Name?

Sarah Phillips | Posted 24.10.2011 | UK
Sarah Phillips

The pharma industry must look beyond the label of patient and see the person behind the disease. If you took a sample of your friends or acquaintances and asked them to describe you, what would they say?